Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
ANIX 
Anixa Biosciences Inc (ANIX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/23/2025: ANIX (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
3 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $9
1 Year Target Price $9
| 1 | Strong Buy |
| 2 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -59.03% | Avg. Invested days 26 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/23/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 132.98M USD | Price to earnings Ratio - | 1Y Target Price 9 |
Price to earnings Ratio - | 1Y Target Price 9 | ||
Volume (30-day avg) 3 | Beta 0.7 | 52 Weeks Range 2.07 - 4.98 | Updated Date 10/22/2025 |
52 Weeks Range 2.07 - 4.98 | Updated Date 10/22/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.34 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Revenue by Geography
Earnings Date
Report Date 2025-09-25 | When - | Estimate -0.085 | Actual -0.07 |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -36.95% | Return on Equity (TTM) -62.15% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 92480650 | Price to Sales(TTM) 481.54 |
Enterprise Value 92480650 | Price to Sales(TTM) 481.54 | ||
Enterprise Value to Revenue 368.98 | Enterprise Value to EBITDA -8.76 | Shares Outstanding 32916915 | Shares Floating 31168368 |
Shares Outstanding 32916915 | Shares Floating 31168368 | ||
Percent Insiders 5.31 | Percent Institutions 16.47 |
Upturn AI SWOT
Anixa Biosciences Inc
Company Overview
History and Background
Anixa Biosciences, Inc. (ANIX) is a biotechnology company focused on developing therapies and vaccines that address critical unmet needs in oncology and infectious diseases. Founded in 2011, it has evolved through strategic acquisitions and a shift towards innovative immunotherapy and vaccine technologies.
Core Business Areas
- Cancer Immunotherapy: Developing novel therapies designed to use the body's immune system to fight cancer. This includes technologies targeting T cell activation and chimeric antigen receptor T-cell (CAR-T) therapy approaches.
- Infectious Disease Vaccine: Developing vaccine that aims to combat infectious disease like COVID-19.
Leadership and Structure
The leadership team consists of Dr. Jose Conejo-Garcia (President and CEO), and other key personnel in research and development, finance, and operations. The organizational structure is typical of a biotech company, with research, clinical development, and corporate functions.
Top Products and Market Share
Key Offerings
- CAR-T Cancer Therapy: Anixa is developing a novel CAR-T therapy that targets the Follicle Stimulating Hormone Receptor (FSHR), which is found on ovarian cancer cells but not on normal tissues, addressing the key issue of on-target/off-tumor toxicity seen with standard CAR-T therapies. Market share data is not yet available, as the product is still in preclinical and clinical development. Competitors include major pharmaceutical companies developing CAR-T therapies, such as Novartis (NVS) and Gilead (GILD).
- Vaccine for Ovarian Cancer: Anixa is developing a vaccine targeting the CTP peptide on nearly all ovarian cancers. Clinical trials are in progress. Market share data is unavailable at this stage. Competitors are other companies in the cancer vaccine space.
- COVID-19 Therapeutic: Anixa is developing a therapeutic that targets a protein found in most coronaviruses. Clinical trials are in progress. Market share data is unavailable at this stage. Competitors are other companies in the antiviral space.
Market Dynamics
Industry Overview
The biotechnology industry is characterized by high risk, high reward ventures focused on developing innovative treatments and diagnostics for diseases. The industry is heavily regulated, with significant investment required for research, development, and clinical trials.
Positioning
Anixa Biosciences is a small-cap biotech company focused on specific unmet needs within oncology and infectious diseases. Its competitive advantage lies in its novel technology platforms and targeted approach.
Total Addressable Market (TAM)
The TAM for cancer immunotherapy and infectious disease vaccines is estimated to be in the tens of billions of dollars. Anixa is positioned to capture a portion of this market with successful clinical development and commercialization of its products.
Upturn SWOT Analysis
Strengths
- Novel technology platforms
- Targeted approach to unmet medical needs
- Strong intellectual property portfolio
- Experienced leadership team
Weaknesses
- Limited financial resources
- Early stage of product development
- High risk of clinical trial failure
- Dependence on key personnel
Opportunities
- Partnerships with larger pharmaceutical companies
- Positive clinical trial results
- Expansion into new therapeutic areas
- Government funding and grants
Threats
- Competition from larger, well-funded companies
- Regulatory hurdles
- Patent challenges
- Economic downturn
Competitors and Market Share
Key Competitors
- NVS
- GILD
- MRNA
- BNTX
Competitive Landscape
Anixa Biosciences faces significant competition from larger, well-funded pharmaceutical companies. It differentiates itself through its novel technology platforms and targeted approach.
Growth Trajectory and Initiatives
Historical Growth: Anixa's historical growth has been characterized by strategic acquisitions and the development of its technology platforms.
Future Projections: Future growth depends on the successful clinical development and commercialization of its products. Analyst estimates vary widely due to the inherent uncertainty in biotech investments.
Recent Initiatives: Recent initiatives include advancing its CAR-T therapy and ovarian cancer vaccine into clinical trials.
Summary
Anixa Biosciences is a high-risk, high-reward biotechnology company focused on innovative therapies for cancer and infectious diseases. Its success depends on positive clinical trial results and successful commercialization. The company faces strong competition from larger players and needs to manage its financial resources carefully.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company SEC Filings
- Analyst Reports
- Company Website
- Third-Party Financial Data Providers
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. Investing in biotechnology companies carries significant risk.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Anixa Biosciences Inc
Exchange NASDAQ | Headquaters San Jose, CA, United States | ||
IPO Launch date 1987-01-01 | CEO, Chairman & Co-Chair of CBAB Dr. Amit Kumar Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 5 | Website https://www.anixa.com |
Full time employees 5 | Website https://www.anixa.com | ||
Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines that are focused on critical unmet needs in oncology. Its therapeutics programs include the development of a chimeric endocrine receptor-T cell therapy, a novel form of chimeric antigen receptor-T cell (CAR-T) technology that is focused on treating ovarian cancer. The company's vaccine programs include the development of a vaccine against breast cancer, initially focused on triple negative breast cancer (TNBC), the most lethal form of breast cancer; and the development of a vaccine against ovarian cancer, as well as a vaccine discovery program to develop additional cancer vaccines to address intractable cancers, including high incidence malignancies in lung, colon, and prostate. Its vaccine technologies focus on the discovery of additional retired proteins that may be associated with other forms of cancer. The company was formerly known as ITUS Corporation and changed its name to Anixa Biosciences, Inc. in October 2018. Anixa Biosciences, Inc. was incorporated in 1982 and is based in San Jose, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.